Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study - Mysler, E; Tanaka, Y; Kavanaugh, A; Aletaha, D; Taylor, PC; Song, IH; Shaw, T; Song, Y; Demasi, R; Ali, M; Fleischmann, R (BMJ Publishing Group, 2021)